The University of Texas MD Anderson Cancer Center and SOPHiA GENETICS announced a strategic collaboration to combine SOPHiA GENETICS’ AI-powered analytics with MD Anderson’s clinical and scientific expertise to accelerate data-driven cancer care and translate diagnostic results into clinical practice.
The partners will launch a series of research and development programs and co-develop an advanced next-generation sequencing oncology test built on the SOPHiA DDM platform. The test aims to convert complex multimodal data into actionable clinical insights at greater speed and scale. MD Anderson researchers will use SOPHiA GENETICS’ AI technologies to create bioinformatics pipelines that help clinicians rapidly interpret complex RNA-sequencing data for cancer diagnosis and treatment decisions.
“Cancer research has evolved rapidly, and we have more health data available than ever before. Our collaboration with SOPHiA GENETICS reflects how our lab is evolving and integrating advanced analytics and AI to better interpret complex molecular information,” said Donna Hansel, M.D., Ph.D., division head of Pathology and Laboratory Medicine at MD Anderson. “This collaboration will expand our ability to translate high-dimensional data into insights that can meaningfully advance research and precision oncology.”
The joint programs will explore methods to characterize tumor evolution in real time, improve the reliability and reproducibility of complex genomic testing, and enhance the ability to match individual patients with optimal clinical trials or research pathways. The collaborative work at MD Anderson will be led by Shashikant Kulkarni, Ph.D., deputy division head for Molecular Pathology, and J. Bryan, M.D., assistant professor in the Division of Pathology and Laboratory Medicine.
“This collaboration with MD Anderson amplifies our shared ambition to push the boundaries of what is possible in cancer research,” said Philippe Menu, M.D., Ph.D., chief product officer and chief medical officer at SOPHiA GENETICS. “With SOPHiA DDM as a unifying analytical layer, we are enabling new discoveries, accelerating breakthroughs in precision oncology and, most importantly, enabling patients around the globe to benefit from these innovations by bringing leading technologies to all geographies quickly and at scale.”
The collaboration is intended to fuel next-generation scientific discovery and equip clinicians and researchers with tools to better understand the dynamic nature of cancer and bring improved diagnostics and therapies into clinical practice.
Leave a Reply